D
David A. Hokey
Researcher at University of Pennsylvania
Publications - 50
Citations - 2378
David A. Hokey is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Vaccination & Tuberculosis vaccines. The author has an hindex of 24, co-authored 50 publications receiving 1997 citations. Previous affiliations of David A. Hokey include Aeras & University of Pittsburgh.
Papers
More filters
Journal ArticleDOI
Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination
Elisa Nemes,Hennie Geldenhuys,Virginie Rozot,Kathryn Tucker Rutkowski,Frances Ratangee,Nicole Bilek,Simbarashe Mabwe,Lebohang Makhethe,Mzwandile Erasmus,Asma Toefy,Humphrey Mulenga,Willem A. Hanekom,Steven G. Self,Linda-Gail Bekker,Ryall Robert P,Sanjay Gurunathan,Carlos A. DiazGranados,Peter Andersen,Ingrid Kromann,Thomas J. Evans,Ruth D. Ellis,Bernard Landry,David A. Hokey,Robert Hopkins,Ann M. Ginsberg,Thomas J. Scriba,Mark Hatherill +26 more
TL;DR: The rate of sustained QFT conversion, which may reflect sustained M. tuberculosis infection, was reduced by vaccination in a high‐transmission setting, and this finding may inform clinical development of new vaccine candidates.
Journal ArticleDOI
A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human.
Jaap T. van Dissel,Simone A. Joosten,Søren T. Hoff,Darius Soonawala,Corine Prins,David A. Hokey,Dawn M. O’Dee,Andrew Graves,Birgit Thierry-Carstensen,Lars Vibe Andreasen,Morten Ruhwald,Adriëtte W. de Visser,Else Marie Agger,Tom H. M. Ottenhoff,Ingrid Kromann,Peter Andersen +15 more
TL;DR: Results show that CAF01 is a safe and tolerable, Th1-inducing adjuvant for human TB vaccination trials and for vaccination studies in general where cellular immunity is required.
Journal ArticleDOI
Immunostimulation of dendritic cells by cationic liposomes.
Dileep Padinjarae Vangasseri,Zhengrong Cui,Weihsu Chen,David A. Hokey,Louis D. Falo,Leaf Huang,Leaf Huang +6 more
TL;DR: A nano-aggregate liposome-polycation-DNA (LPD), composed of a cationic lipid, protamine and plasmid DNA was found to effectively deliver a human papillomavirus-E7 epitope antigen to the antigen presenting cells of the immune system, eliciting enhanced anti-tumor immune responses in mouse models of cervical carcinoma.
Journal ArticleDOI
Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques.
Lauren A. Hirao,Ling Wu,Amir S. Khan,David A. Hokey,Jian Yan,Anlan Dai,Michael R. Betts,Ruxandra Draghia-Akli,David B. Weiner +8 more
TL;DR: A pilot study in rhesus macaques suggests that adjuvant and improved delivery methods may be able to overcome previous immunogenicity limitations in DNA vaccine technology.
Journal ArticleDOI
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial.
Rhea N. Coler,Tracey A. Day,Ruth D. Ellis,Franco M. Piazza,Anna Marie Beckmann,Julie Vergara,Tom Rolf,Lenette L. Lu,Galit Alter,David A. Hokey,Lakshmi Jayashankar,Robert L. Walker,Margaret A Snowden,Thomas J. Evans,Ann M. Ginsberg,Steven G. Reed +15 more
TL;DR: A tuberculosis vaccine containing an immunity-potentiating agent stimulated strong immune responses in a first-in-human trial and demonstrated an acceptable safety profile and indicated that the GLA-SE adjuvant drives a functional humoral and T-helper 1 type cellular response.